Mumbai-based Zota Health Care has successfully raised ₹350 crore through a Qualified Institutional Placement (QIP) and committed the entire proceeds to accelerate the expansion of its retail pharmacy chain, Dava India (Davaindia Generic Pharmacy), targeting up to 1,500 new stores across India over the next two years to boost access to affordable generic medicines.
Glimpse:
Zota Health Care closed its QIP at ₹350 crore (originally planned up to ₹500 crore with green shoe option) and will deploy all funds exclusively into Dava India, its fast-growing generic pharmacy brand. The aggressive rollout aims to capitalize on rising demand for low-cost, high-quality generics in India’s fragmented retail pharma market, with each store projected to generate ₹2-2.5 lakh monthly initially, scaling to ₹6-7 lakh within 3-4 years. This move strengthens Zota’s position in organized retail amid government support for generics.
Zota Health Care Ltd., a leading integrated pharmaceutical company, has locked in ₹350 crore from a Qualified Institutional Placement (QIP) and pledged every rupee to supercharge its retail pharmacy arm, Dava India. The fundraising, which concluded successfully with the allotment of 22.8 lakh equity shares at ₹1,535 per share, marks a bold step to dominate the organized generic pharmacy space in India.
Dava India (Davaindia Generic Pharmacy), a wholly owned subsidiary, focuses on delivering high-quality unbranded generic medicines at prices up to 90% lower than branded alternatives. By eliminating multiple intermediaries in the supply chain, it passes substantial savings directly to consumers while maintaining transparency and quality—aligning perfectly with national policies promoting generics and affordable healthcare.
The fresh capital will fuel an aggressive expansion drive: up to 1,500 new stores planned over the next two years, building on the brand’s steady growth. Dava India operates through a hybrid model of Company Owned Company Operated (COCO) and Franchisee Owned Franchisee Operated (FOFO) stores, enabling rapid scaling with controlled capital intensity.
Early-stage stores are expected to clock monthly revenues of ₹2-2.5 lakh, with mature outlets (after 3-4 years) reaching ₹6-7 lakh as footfall and local brand awareness build. This revenue trajectory underscores the model’s viability in tier-II/III cities and beyond, where demand for cost-effective medicines remains high.
Zota Health Care, headquartered in Mumbai (with roots in Surat), already spans drug manufacturing, marketing, distribution, exports to over 30 countries, and a growing retail footprint. The Dava India push positions it to capture more value in the retail interface, where customer loyalty and margins are strongest.
This investment reflects strong institutional confidence in Zota’s strategy amid India’s evolving pharma retail landscape, driven by consumer preference for affordability, transparent pricing, and easy access. It also complements broader digital and e-pharmacy initiatives, including the brand’s B2C online portal and app.
“Originally, we had planned up to Rs 500 crore, but later the management decided to raise Rs 300 crore plus Rs 100 crore green shoe option. The QIP closed successfully at Rs 350 crore. In the same light, we will open more stores of Dava India.”
By
HB Team
